Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pancreatic beta cell autoreactive T lymphocytes are immune cells—primarily CD8⁺ and CD4⁺ T cells—that specifically recognize and attack antigens derived from pancreatic beta cells, leading to their destruction. In type 1 diabetes, these autoreactive T cells respond to islet autoantigens such as insulin, glutamic acid decarboxylase (GAD65), IA-2, and islet-specific glucose-6-phosphate catalytic subunit–related protein (IGRP), among others. The loss of beta cell mass and insulin production from autoimmune activity by these T cells ultimately results in insulin-dependent diabetes. They are not a single molecular entity or therapeutic target but rather a functional cell population defined by their pathogenic autoimmune activity.
Suppression or modulation of autoreactive T cell activity, immune tolerance induction
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pancreatic beta cell autoreactive T lymphocyte function.